Emerging drugs for irritable bowel syndrome

Expert Opinion on Emerging Drugs

Volumn 11, Issue 2, 2006, Pages 293-313

  Bradesi, Sylvie ^a,b   Tillisch, Kirsten ^c   Mayer, Emeran ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain gut axis; Chloride channels; Constipation; Corticotropin releasing factor; Diarrhoea; Irritable bowel syndrome; Neurokinin; Noradrenergic system; Opioids; Probiotics; Serotonin; Visceral pain

Indexed keywords

AGI 003; ALOSETRON; ASIMADOLINE; ATI 17000; CHOLINERGIC RECEPTOR BLOCKING AGENT; CILANSETRON; CIMETROPIUM; DDP 225; DEXLOXIGLUMIDE; DICYCLOVERINE; HYOSCYAMINE SULFATE; ISPAGULA; LOPERAMIDE; LUBIPROSTONE; MEBEVERINE; NALTREXONE; OPIATE AGONIST; OTILONIUM BROMIDE; PINAVERIUM BROMIDE; PUMOSETRAG; RENZAPRIDE; SCOPOLAMINE BUTYL BROMIDE; SEROTONIN AGONIST; SLV 317; SLV 332; TACHYKININ RECEPTOR ANTAGONIST; TALNETANT; TEGASEROD; TRIMEBUTINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLOATING; CLINICAL TRIAL; CONSTIPATION; DEFECATION HABIT; DIARRHEA; DIET SUPPLEMENTATION; DRUG ACTIVITY; HEADACHE; HUMAN; INTESTINE MOTILITY; INTESTINE SECRETION; IRRITABLE COLON; ISCHEMIC COLITIS; LOOSE FECES; META ANALYSIS; MUCOSAL IMMUNITY; MUSCLE CRAMP; NONHUMAN; PAIN; PATHOPHYSIOLOGY; PATIENT SATISFACTION; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URINARY URGENCY;

DRUGS, INVESTIGATIONAL; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; SEROTONIN AGENTS;

EID: 33646546724     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.11.2.293     Document Type: Review

References (167)

1. DROSSMANDA, CAMILLERI M, MAYER EA, WHITEHEAD WE: AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 123(6):2108-2131.
2. MAYER EA, NALIBOFF BD, CHANG L, COUTINHO SV: Stress and irritable bowel syndrome. Am. J. Physiol. Gastrointest. Liver. Physiol. (2001) 280(4):G519-G524.
3. THOMPSON WG, LONGSTRETH GF, DROSSMAN DA, HEATON KW, IRVINE EJ, MULLER-LISSNER SA: Functional bowel disorders and functional abdominal pain. Gut (1999) 45(2):II43-II47.
4. TILLISCH K, LABUS JS, NALIBOFF BD et al.: Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome. Am. J. Gastroenterol. (2005) 100(4):896-904.
5. HUNGIN AP, CHANG L, LOCKE GR, DENNIS EH, BARGHOUT V: Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment. Pharmacol. Ther. (2005) 21(11):1365-1375.
6. DEAN BB, AGUILAR D, BARGHOUT V et al.: Impairment in work productivity and health-related quality of life in patients with IBS. Am. J. Manag. Care. (2005) 11(1):S17-S26.
7. SPIEGEL BM, GRALNEK IM, BOLUS R et al.: Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch. Intern. Med. (2004) 164(16):1773-1780.
8. INADOMI JM, FENNERTY MB, BJORKMAN D: Systematic review: the economic impact of irritable bowel syndrome. Aliment. Pharmacol. Ther. (2003) 18(7):671-682.
9. SCHWETZ I, BRADESI S, MAYER EA: The pathophysiology of irritable bowel syndrome. Minerva Med. (2004) 95(5):419-426.
10. MULAK A, BONAZ B: Irritable bowel syndrome: a model of the brain-gut interactions. Med. Sci. Monit. (2004) 10(4):55-62.
11. MAYER EA, BERMAN S, SUYENOBU B et al.: Differences in brain responses to visceral pain between patients with irritable bowel syndrome and ulcerative colitis. Pain (2005) 115(3):398-409.
12. MERTZ H, MORGAN V, TANNER G et al.: Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology (2000) 118(5):842-848.
13. MAYER EA, COLLINS SM: Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology (2002) 122(7):2032-2048. Comprehensive review of evidence for peripheral and central mechanisms contributing to symptom generation in IBS.
14. TOLLIVER BA, HERRERA JL, DIPALMA JA: Evaluation of patients who meet clinical criteria for irritable bowel syndrome. Am. J. Gastroenterol. (1994) 89(2):176-178.
15. SANDERS DS, CARTER MJ, HURLSTONE DP et al.: Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet (2001) 358(9292):1504-1508.
16. CHADWICK VS, CHEN W, SHU D et al.: Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology (2002) 122:1778-1783.
17. CAMILLERI M, ATANASOVA E, CARLSON PJ et al.: Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology (2002) 123(2):425-432.
18. SOMERS SC, LEMBO A: Irritable bowel syndrome: evaluation and treatment. Gastroenterol. Clin. North Am. (2003) 32(2):507-529.
19. DROSSMAN DA, THOMPSON WG: The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann. Intern. Med. (1992) 116(12 Pt 1):1009-1016.
20. OBERNDORFF-KLEIN WOOLTHUIS AH, BRUMMER RJ, DE WIT NJ, MURIS JW, STOCKBRUGGER RW: Irritable bowel syndrome in general practice: an overview. Scand. J. Gastroenterol Suppl. (2004) 241:17-22.
21. BRANDT LJ, BJORKMAN D, FENNERTY MB et al.: Systematic review on the management of irritable bowel syndrome in North America. Am. J. Gastroenterol. (2002) 97(11):S7-S26. Extensive review of the literature on the epidemiology and current therapeutic strategies for IBS.
22. MERTZ H: Psychotherapeutics and serotonin agonists and antagonists. J. Clin. Gastroenterol. (2005) 39(1):247-250.
23. ATKINSON W, SHELDON TA, SHAATH N, WHORWELL PJ: Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut (2004) 53(10):1459-1464.
24. ADDOLORATO G, MARSIGLI L, CAPRISTO E, CAPUTO F, DALL'AGLIO C, BAUDANZA P: Anxiety and depression: a common feature of health care seeking patients with irritable bowel syndrome and food allergy. Hepatogastroenterology (1998) 45(23):1559-1564.
25. JAILWALA J, IMPERIALE TF, KROENKE K: Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann. Intern. Med. (2000) 133(2):136-147.
26. POYNARD T NAVEAU S, MORY B, CHAPUT JC: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. (1994) 8(5):499-510.
27. POYNARD T REGIMBEAU C, BENHAMOU Y: Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. (2001) 15(3):355-361.
28. HOVDENAK N: Loperamide treatment of the irritable bowel syndrome. Scand. J. Gastroenterol. Suppl. (1987) 130:81-84.
29. CANN PA, READ NW, HOLDSWORTH CD, BARENDS D: Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig. Dis. Sci. (1984) 29(3):239-247.
30. EFSKIND PS, BERNKLEV T, VATN MH: A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand. J. Gastroenterol. (1996) 31(5):463-468.
31. CLOUSE RE: Antidepressants for irritable bowel syndrome. Gut (2003) 52(4):598-599.
32. JACKSON JL, O'MALLEY PG, TOMKINS G, BALDEN E, SANTORO J, KROENKE K: Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am. J. Med. (2000) 108(1):65-72.
33. DROSSMAN DA, TONER BB, WHITEHEAD WE et al.: Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology (2003) 125(1):19-31.
34. TABAS G, BEAVES M, WANG J, FRIDAY P, MARDINI H, ARNOLD G: Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am. J. Gastroenterol. (2004) 99(5):914-920.
35. CREED F, FERNANDES L, GUTHRIE E et al.: North of England IBS Research Group. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology (2003) 124(2):303-317.
36. BARKIN R, BARKIN SJ: Antidepressants for the management of pain in geriatric patients. Anesth. Today (2004) 15:23-26.
37. BRADLEY RH, BARKIN RL, JEROME J et al.: Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am. J. Ther. (2003) 10:318-323.
38. WESTANMO AD, GAYKEN J, HAIGHT R: Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. Am. J. Health. Syst. Pharm. (2005) 62(23):2481-2490.
39. RASKIN J, PRITCHETT YL, WANG F et al.: A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. (2005) 6(5):346-356.
40. GERSHON MD: Plasticity in serotonin control mechanisms in the gut. Curr. Opin. Pharmacol. (2003) 3(6):600-607.
41. GERSHON MD: Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Aliment. Pharmacol. Ther. (2004) 20(7):3-14.
42. ORLICZ-SZCZESNA G, ZABEL M, JAROSZEWSKIJ: The effect of stress induced experimental gastric ulcers on enterochromaffin cells and on serotonin and 5-hydroxyindolacetic acid levels in stomach and duodenum of the white rat. Z. Mikrosk. Anat. Forsch. (1989) 103(3):504-514.
43. GERSHON MD: Serotonin and its implication for the management of irritable bowel syndrome. Rev. Gastroenterol. Disord. (2003) 3(2):S25-S34.
44. DUNLOP SP, JENKINS D, NEAL KR, SPILLER RC: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology (2003) 125(6):1651-9.
45. SPILLER RC, JENKINS D, THORNLEY JP et al.: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut (2000) 47(6):804-811.
46. COATES MD, MAHONEY CR, LINDEN DR et al.: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology (2004) 126(7):1657-1664. This study shows significant molecular alterations of the serotoninergic system specific to the gut in IBS patients.
47. MAWE GM, BRANCHEK TA, GERSHON MD: Peripheral neural serotonin receptors: identification and characterization with specific antagonists and agonists. Proc. Natl. Acad. Sci. USA (1986) 83:9799-9803.
48. RAYBOULD HE, GLATZLE J, ROBIN C et al.: Expression of 5-HT3Rs by extrinsic duodenal afferents contributes to intestinal inhibition of gastric emptying. Am. J. Physiol. Gastrointest. Liver. Physiol. (2003) 284:G367-G372.
49. 4 receptors. FASEB J. (1996) 10(12):1398-1407.
50. CAMILLERI M: Review article: tegaserod. Aliment. Pharmacol. Ther. (2001) 15(3):277-289.
51. SCHIKOWSKI A, THEWISSEN M, MATHIS C, ROSS HG, ENCK P: Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol. Motil. (2002) 14(3):221-227.
52. 4 receptor. 1. Design of a new class of agonists and receptor map of the agonist recognition site. J. Med. Chem. (1995) 38(13):2326-2330.
53. MAYER EA, FANSELOW MS: Dissecting the components of the central response to stress. Nat. Neurosci. (2003) 6(10):1011-1012.
54. TACHÉ Y: Stress-induced alterations of gastric emptying. In: Stress and Digestive Motility. L Bueno, S Collins, JL Junien (Eds), John Libbey Eurotext, Montrouge, France (1989):123-132.
55. TACHE Y, MARTINEZ V, MILLION M, WANG L: Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am. J. Physiol. Gastrointest. Liver Physiol. (2001) 280(2):G173-G177. Comprehensive review on the role of CRF in stress-induced alterations of gastrointestinal motor function.
56. RAO SS, HATFIELD RA, SULS JM, CHAMBERLAIN MJ: Psychological and physical stress induce differential effects on human colonie motility. Am. J. Gastroenterol. (1998) 93(6):985-990.
57. STANGHELLINI V, MALAGELADA JR, ZINSMEISTER AR, GO VL, KAO PC: Stress-induced gastroduodenal motor disturbances in humans: possible humoral mechanisms. Gastroenterology (1983) 85(1):83-91.
58. WELGAN P, MESHKINPOUR H, MA L: Role of anger in antral motor activity in irritable bowel syndrome. Dig. Dis. Sci. (2000) 45(2):248-251.
59. MONNIKES H, TEBBE JJ, HILDEBRANDT M: Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity. Dig. Dis. (2001) 19(3):201-211.
60. GUE M, DEL RIO-LACHEZE C, EUTAMENE H, THEODOROU V, FIORAMONTI J, BUENO L: Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol. Motil. (1997) 9(4):271-279.
61. BRADESI S, EUTAMENE H, GARCIA-VILLAR R, FIORAMONTI J, BUENO L: Acute and chronic stress differently affect visceral sensitivity to rectal distension in female rats. Neurogastroenterol. Motil. (2002) 14(1):75-82.
62. SCHWETZ I, MCROBERTS JA, COUTINHO SV et al.: Corticotropin-releasing factor receptor 1 mediates acute and delayed stress-induced visceral hyperalgesia in maternally separated Long-Evans rats. Am. J. Physiol. Gastrointest. Liver. Physiol. (2005) 289(4):G704-G712.
63. TACHE Y, MARTINEZ V, WANG L, MILLION M: CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br. J. Pharmacol. (2004) 141(8):1321-1330.
64. 1 receptor-mediated mechanisms regulate colonic hypersensitivity in the guinea pig. Pharmacol. Biochem. Behav. (2003) 74(4):1005-1013.
65. 1 receptors. Gastroenterology (2005) 128:A494.
66. BERCIK P, VERDU EF, COLLINS SM: Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol. Clin. North. Am. (2005) 34(2):235-245.
67. WESTON AP, BIDDLE WL, BHATIA PS, MINER PB Jr: Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig. Dis. Sci. (1993) 38(9):1590-1595.
68. O'SULLLVAN M, CLAYTON N, BRESLIN N et al.: Increased mast cells in the irritable bowel syndrome. Neurogastroenterol. Motil. (2000) 12(5):449-457.
69. TORNBLOM H, LINDBERG G, NYBERG B et al.: Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology (2002) 123:1972-1979.
70. BARBARA G, STANGHELLINI V, DE GIORGIO R et al.: Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology (2004) 126:693-702. Interesting study assessing the correlation between colonic mast cell infiltration, mediator release and spatial interactions with mucosal innervation in IBS patients.
71. BARBARA G, COTTRELL G, GRADY E et al.: Expression and release of mast cell tryptase in irritable bowel syndrome (IBS). Gastroenterology (2002) 126(3):693-702.
72. BARBARA G, CREMON C, RICCARDO V et al.: Colonic mucosal mast cell mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. Digestive Diseases Week (2005) Abstract ID403.
73. BARBARA G, STANG HELLINI V, DE GIORGIO R et al.: Neuroimmune relationships in the colonic mucosa of irritable bowel syndrome patients. Neurogastroenterol. Motil. (2000) 12:A272.
74. BARBARA G, WANG B, GRUNDY D et al.: Mast cells are increased in the colonic mucosa of patients with irritable bowel syndrome and excite visceral sensory pathways. Digestive Disease Week (2005) Abstract IDW1503.
75. GWEE KA, COLLINS SM, MARSHALL JS et al.: Evidence of inflammatory pathogenesis in post-infectious irritable bowel syndrome. Gastroenterology (1998) 114:A758.
76. GWEE KA, COLLINS SM, READ NW et al.: Increased rectal mucosal expression of interleukin 1β in recently acquired post-infectious irritable bowel syndrome. Gut (2003) 52:523-526.
77. WANG LH, FANG XC, PAN GZ: Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. (2004) 53:1096-1101.
78. BALSARI A, CECCARELLI A, DUBINI F et al.: The fecal microbial population in the irritable bowel syndrome. Microbiologica. (1982) 5:185-194.
79. O'LEARY C, QUIGLEY EM: Small bowel bacterial overgrowth, celiac disease, and IBS: what are the real associations? Am. J. Gastroenterol. (2003) 98(4):720-722.
80. PIMENTEL M, CHOW EJ, LIN HC et al.: Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am. J. Gastroenterol. (2000) 95:3503-3506.
81. SWDSINSKI A, KHILKIN M, ORTNER M et al.: Alteration of bacterial concentration in colonic biopsies from patients with irritable bowel syndrome (IBS). Gastroenterology (1999) 116:A1.
82. PIMENTEL M: Do antibiotics influence IBS? Am. J. Gastroenterol. (2002) 97(10):2681.
83. PIMENTEL M, CHOW EJ, LIN HC: Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome - a double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol. (2003) 98(2):412-419. This study reports the first evidence of a beneficial effect of antibiotic treatment on gastrointestinal symptoms in IBS patients.
84. MADDEN JA, HUNTER JO: A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics. Br. J. Nutr. (2002) 88(1):S67-S72.
85. CHAN J, GONSALKORALE WM, PERREY C et al.: IL-10 and TGF-β genotypes in irritable bowel syndrome: evidence to support an inflammatory component? Gastroenterology (2000) 1191:A184.
86. DUNLOP S, JENKINS D, NAESDAL J et al.: Randomised double-blind placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Gastroenterology (2002) 499:A60.
87. CAMILLERI M, NORTHCUTT AR, KONG S, DUKES GE, MCSORLEY D, MANGEL AW: Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet (2000) 355(9209):1035-1040.
88. CAMILLERI M, CHEY WY, MAYER EA et al.: A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch. Intern. Med. (2001) 161(14):1733-1740.
89. LEMBO T, WRIGHT RA, BAGBY B et al.: Lotronex Investigator Team. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. (2001) 96(9):2662-2670.
90. CHANG L, AMEEN VZ, DUKES GE, MCSORLEY DJ, CARTER EG, MAYER EA: A dose-ranging, Phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am. J. Gastroenterol. (2005) 100:115-123.
91. 3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment. Pharmacol. Ther. (2000) 14(6):775-782.
92. DELVAUX M, LOUVEL D, MAMET JP, CAMPOS-ORIOLA R, FREXINOS J: Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. (1998) 12(9):849-855.
93. 3R antagonist Alosetron. Gastroenterology (2002) 123:969-977.
94. 3R antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment. Pharmacol. Ther. (2002) 16:1357-1366.
95. 3R antagonist. Dig. Dis. Sci. (1999) 44:20-24.
96. HORTON R: Lotronex and the FDA: a fatal erosion of integrity. Lancet (2001) 357:1544-5.
97. FRIEDEL D, THOMAS R, FISHER RS: Ischemic colitis during treatment with alosetron. Gastroenterology (2001) 120:557-560.
98. KOVAL G, OLDEN KW, CARTER F, KRAUSE G, CARAS S, STEIBORN C: Long term safety and tolerability of cilansetron 2 mg when used as needed (PRN) in patients with irritable bowel syndrome with diarrhea predominance (IBD-D). Digestive Diseases Week (2005).
99. MINER PB, PRUITT RE, CARTER F, CARAS S, KRAUSE G, STEIBORN C: Cilansetron is efficacious in treating diarrheal symptoms in Irritable bowel symdrom with diarrhea predominance (IBS-D) over 3 months. Digestive Diseases Week (2005).
100. CHEY WD, CASH BD: Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea. Expert Opin. Investig. Drugs (2005) 14(2):185-193.
101. YAMAZAKI S, YANO T, OGAWA S, TOBE A: Effects of MKC-733, a new prokinetic compound, on gastrointestinal motility in rats and dogs. Jpn. J. Pharmacol. (1995) 67(1):189.
102. 3 receptor agonist MKC-733 on upper gastrointestinal motility in humans. Aliment. Pharmacol. Ther. (2003) 18(10):1039-1048.
103. 4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment. Pharmacol. Ther. (2001) 15(11):1745-1751.
104. PRATHER CM, CAMILLERI M, ZINSMEISTER AR, MCKINZIE S, THOMFORDE G: Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology (2000) 118(3):463-468.
105. WAGSTAFF AJ, FRAMPTON JE, CROOM KF: Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women. Drugs (2003) 63(11):1101-1120.
106. CRAIG DA, CLARKE DE: Pharmacological characterization of a neuronal receptor for 5-hydroxytryptamine in guinea pig ileum with properties similar to the 5-hydroxytryptamine receptor. J. Pharmacol. Exp. Ther. (1990) 252(3):1378-1386.
107. MULLER-LISSNER SA, FUMAGALLI I, BARDHAN KD et al.: Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment. Pharmacol. Ther. (2001) 15(10):1655-1666.
108. KELLOW J, LEE OY, CHANG FY et al.: An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut (2003)) 52(5):671-676.
109. TOUGAS G, SNAPE WJ JR, OTTEN MH et al.: Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. (2002) 16(10):1701-1708.
110. JOHANSON JF: Review article: tegaserod for chronic constipation. Aliment. Pharmacol. Ther. (2004) 20(7):20-24.
111. GEORGE A, MEYERS NI, PALMER RMJ: Efficacy and safety of renzapride in patients with constipation-predominant IBS: a Phase IIb study in the UK primary healthcare setting. Gut (2005) 52(Suppl. VI):A91.
112. CAMILLERI M, MCKINZIE S, FOX J et al.: Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin. Gastroenterol. Hepatol. (2004) 2(10):895-904.
113. 1A receptors. Eur. J. Pharmacol. (1991) 202(3):379-383.
114. TACK J, PIESSEVAUX H, COULIE B, CAENEPEEL P, JANSSENS J: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology (1998) 115(6):1346-1352.
115. 1A agonist buprizone on rectal tone and the perception of rectal distension in man. Gastroenterology (2005) 114:G3046.
116. CHIAL HJ, CAMILLERI M, FERBER I et al.: Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin. Gastroenterol. Hepatol. (2003) 1(3):211-218.
117. 1 receptor agonist, induces a lag phase for gastric emptying of liquids in humans. Am. J. Physiol. (1997) 272(4Pt1):G902-G908.
118. ARNOLD LM, ROSEN A, PRITCHETT YL et al.: A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain (2005) 119(1-3):5-15.
119. 1 (substance P) receptor antagonists-why are they not analgesic in humans? Trends. Pharmacol. Sci. (2000) 21(7):244-246.
120. 1 receptor have a role in depression and anxiety? Curr. Pharm. Des. (2005) 11(12):1529-1547.
121. 1 receptor. Part II: Distribution and pathophysiological roles. Neuropeptides (1998) 32(1):1-49.
122. OKANO S, NAGAYA H, IKEURA Y, NATSUGARI H, INATOMI N: Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo. J. Pharmacol. Exp. Ther. (2001) 298(2):559-564.
123. 1 receptors in the rabbit isolated distal colon. Am. J. Physiol. Gastrointest. Liver Physiol. (2003) 285(2):G325-G331.
124. 1 receptor antagonists on the viscerosensory response caused by colorectal distention in rabbits. J. Pharmacol. Exp. Ther. (2002) 300(3):925-931.
125. GOLDSTEIN DJ, WANG O, GITTER BD, IYENGAR S: Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy. Clin. Neuropharmacol. (2001) 24(1):16-22.
126. STOUT SC, OWENS MJ, NEMEROFF CB: Neurokinin(1) receptor antagonists as potential antidepressants. Ann. Rev. Pharmacol. Toxicol. (2001) 41:877-906.
127. 1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer (2003) 97(9):2290-2300.
128. LEE OY, MUNAKATA J, NALIBOFF BD, CHAND L, MAYER EA: A double blind parallel group pilot study of the effect of CJ-11,934 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. Digestive Diseases Week (2002).
129. 2 receptor antagonists for the treatment of irritable bowel syndrome. Br. J. Pharmacol. (2004) 141(8):1249-1263.
130. DABLEH LJ, YASHPAL K, ROCHFORD J, HENRY JL: Antidepressant-like effects of neurokinin receptor antagonists in the forced swim test in the rat. Eur. J. Pharmacol. (2005) 507(1-3):99-105.
131. SANTICIOLI P, GIULIANI S, PATACCHINI R, TRAMONTANA M, CRISCUOLI M, MAGGI CA: MEN-11420, a potent and selective tachykinin NK2 receptor antagonist in the guinea-pig and human colon. Naunyn. Schmiedebergs. Arch. Pharmacol. (1997) 356(5):678-688.
132. PATACCHINI R, GIULIANI S, TURINI A, NAVARRA G, MAGGI CA: Effect of nepadutant at tachykinin NK(2) receptors in human intestine and urinary bladder. Eur. J. Pharmacol. (2000) 398(3):389-397.
133. 2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br. J. Pharmacol. (2001) 134(1):215-223.
134. 3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain. Br. J. Pharmacol. (2004) 141(8):1303-1312. Discussion of evidence of the role of neurokinins in gastrointestinal dysfunctions and their implication as potential therapeutic targets for IBS.
135. HOLDEN JE, JEONG Y, FORREST JM: The endogenous opioid system and clinical pain management. AACN Clin. Issues (2005) 16(3):291-301.
136. LANGLOIS A, DIOP L, FRIESE N et al.: Fedotozine blocks hypersensitive visceral pain in conscious rats: action at peripheral kappa-opioid receptors. Eur. J. Pharmacol. (1997) 324(2-3):211-217.
137. OZAKI N, SENGUPTA JN, GEBHART GF: Differential effects of μ-, δ-, and κ-opioid receptor agonists on mechanosensitive gastric vagal afferent fibers in the rat. J. Neurophysiol. (2000) 83(4):2209-2216.
138. SU X, WACHTEL RE, GEBHART GF: Inhibition of calcium currents in rat colon sensory neurons by κ- but not μ- or δ-opioids. J. Neurophysiol. (1998) 80(6):3112-3129.
139. DAPOIGNY M, ABITBOL JL, FRAITAG B: Efficacy of peripheral κ-agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multi-center dose-response study. Dig. Dis. Sci. (1995) 40(10):2244-2249.
140. DELVAUX M, LOUVEL D, LAGIER E, SCHERRER B, ABITBOL JL, FREXINOS J: The κ-agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology (1999) 116(1):38-45.
141. DELVAUX M, BECK A, JACOB J et al.: Effect of asimadoline, a κ-opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. (2004) 20(2):237-246.
142. HAWKES ND, RHODES J, EVANS BK, RHODES P, HAWTHORNE AB, THOMAS GA: Naloxone treatment for irritable bowel syndrome - a randomized controlled trial with an oral formulation. Aliment. Pharmacol. Ther. (2002) 16(9):1649-1654.
143. GONENNE J, CAMILLERI M, FERBER I et al.: Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin. Gastroenterol. Hepatol. (2005) 3(8):784-791.
144. TACHE Y, MILLION M, NELSON AG, LAMY C, WANG L: Role of corticotropin-releasing factor pathways in stress-related alterations of colonic motor function and viscerosensibility in female rodents. Gend. Med. (2005) 2(3):146-154.
145. TACHE Y, MARTINEZ V, MILLION M, MAILLOT C: Role of corticotropin releasing factor receptor subtype 1 in stress-related functional colonic alterations: implications in irritable bowel syndrome. Eur. J. Surg. Suppl. (2002) 587:16-22.
146. HABIB KE, WELD KP, RICE KC et al.: Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc. Natl. Acad. Sci. USA (2000) 97(11):6079-6084.
147. MAILLOT C, MILLION M, WEI JY, GAUTHIER A, TACHE Y: Peripheral corticotropin-releasing factor and stress-stimulated colonic motor activity involve type 1 receptor in rats. Gastroenterology (2000) 119(6):1569-1579.
148. MIAMPAMBA M, MAILLOT C, MILLION M, TACHE Y: Peripheral CRF activates myenteric neurons in the proximal colon through CRF(1) receptor in conscious rats. Am. J. Physiol. Gastrointest. Liver Physiol. (2002) 282(5):G857-G865.
149. SAGAMI Y, SHIMADA Y, TAYAMA J et al.: Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut (2004) 53(7):958-964.
150. KIM HJ, CAMILLERI M, CARLSON PJ et a.: Association of distinct α(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut (2004) 53(6):829-837.
151. DIATCHENKO L, SLADE GD, NACKLEY AG et al.: Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum. Mol. Genet. (2005) 14(1):135-143.
152. BHARUCHA AE, CAMILLERI M, ZINSMEISTER AR, HANSON RB: Adrenergic modulation of human colonic motor and sensory function. Am. J. Physiol. (1997) 273(5 Pt 1):G997-G1006.
153. MALCOLM A, PHILLIPS SF, CAMILLERI M, HANSON RB: Pharmacological modulation of rectal tone alters perception of distention in humans. Am. J. Gastroenterol. (1997) 92(11):2073-2079.
154. CAMILLERI M, KIM DY, MCKINZIE S et al.: A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin. Gastroenterol. Hepatol. (2003) 1(2):111-121.
155. VAN DE WALL EH, DUFFY P, RITTER RC: CCK enhances response to gastric distension by acting on capsaicin-insensitive vagal afferents. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 289(3):R695-R703.
156. 1 receptors in colonic motor function. Br. J. Pharmacol. (2004) 141(8):1275-1284.
157. LAL S, MCLAUGHLIN J, BARLOW J et al.: Cholecystokinin pathways modulate sensations induced by gastric distension in humans. Am. J. Physiol. Gastrointest. Liver Physiol. (2004) 287(1):G72-G79.
158. RITTER RC: Increased food intake and CCK receptor antagonists: beyond abdominal vagal afferents. Am J. Physiol. Regul. Integr. Comp. Physiol. (2004) 286(6):R991-R993.
159. FRIED M, FEINLE C: The role of fat and cholecystokinin in functional dyspepsia. Gut (2002) 51(1):54-57.
160. REDDIX RA, LIU X, MILLER MJ, NIU X, POWELL A: Constitutive nitric oxide release modulates neurally-evoked chloride secretion in guinea pig colon. Auton. Neurosci. (2000) 86(1-2):47-57.
161. FARRUGIA G: Ionic conductances in gastrointestinal smooth muscles and interstitial cells of Cajal. Ann. Rev. Physiol. (1999) 61:45-84.
162. BRYANT AP, BUSBY RW, CORDERO EA et at.: MD-1100, a therapeutic agent in development for the treatment of IBS-C, enhances intestinal secretion and transit, decreases visceral pain and is minimally absorbed in rats. Digestive Diseases Week (2005) Abstract IDT1135.
163. HOLZER P: TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia. Eur. J. Pharmacol. (2004) 500(1-3):231-241.
164. FLOCH MH, MONTROSE DC: Use of probiotics in humans: an analysis of the literature. Gastroenterol. Clin. North Am. (2005) 34(3):547-570.
165. NIV E, NAFTALI T, HALLAK R, VAISMAN N: The efficacy of Lactobacillus reuteri ATCC-55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clin Nutr. (2005) 24(6):925-931.
166. O'MAHONY L, MCCARTHY J, KELLY P et al.: Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology (2005) 128(3):541-551.
167. LUPASCU A, GABRIELLI M, LAURITANO EC et al.: Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. Aliment. Pharmacol. Ther. (2005) 22(11-12):1157-1160.